Kangstem Biotech Statistics

Total Valuation

Kangstem Biotech has a market cap or net worth of KRW 116.03 billion. The enterprise value is 97.82 billion.

Market Cap	116.03B
Enterprise Value	97.82B

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Kangstem Biotech has 56.05 million shares outstanding. The number of shares has increased by 42.69% in one year.

Current Share Class	n/a
Shares Outstanding	56.05M
Shares Change (YoY)	+42.69%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	5.94%
Owned by Institutions (%)	0.19%
Float	44.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.77
PB Ratio	2.44
P/TBV Ratio	2.46
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.81
EV / Sales	7.66
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.09

Financial Position

The company has a current ratio of 2.97, with a Debt / Equity ratio of 0.16.

Current Ratio	2.97
Quick Ratio	2.23
Debt / Equity	0.16
Debt / EBITDA	n/a
Debt / FCF	-0.47
Interest Coverage	-22.02

Financial Efficiency

Return on equity (ROE) is -26.14% and return on invested capital (ROIC) is -23.74%.

Return on Equity (ROE)	-26.14%
Return on Assets (ROA)	-19.06%
Return on Capital (ROIC)	-23.74%
Revenue Per Employee	131.70M
Profits Per Employee	-85.37M
Employee Count	97
Asset Turnover	0.20
Inventory Turnover	14.77

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.42% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-10.42%
50-Day Moving Average	2,170.50
200-Day Moving Average	2,175.50
Relative Strength Index (RSI)	45.66
Average Volume (20 Days)	1,192,688

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kangstem Biotech had revenue of KRW 12.77 billion and -8.28 billion in losses. Loss per share was -152.96.

Revenue	12.77B
Gross Profit	1.78B
Operating Income	-19.60B
Pretax Income	-10.74B
Net Income	-8.28B
EBITDA	-16.16B
EBIT	-19.60B
Loss Per Share	-152.96

Full Income Statement

Balance Sheet

The company has 25.82 billion in cash and 7.61 billion in debt, giving a net cash position of 18.21 billion or 324.88 per share.

Cash & Cash Equivalents	25.82B
Total Debt	7.61B
Net Cash	18.21B
Net Cash Per Share	324.88
Equity (Book Value)	47.46B
Book Value Per Share	846.66
Working Capital	23.80B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -14.58 billion and capital expenditures -1.48 billion, giving a free cash flow of -16.06 billion.

Operating Cash Flow	-14.58B
Capital Expenditures	-1.48B
Free Cash Flow	-16.06B
FCF Per Share	-286.44

Full Cash Flow Statement

Margins

Gross margin is 13.91%, with operating and profit margins of -153.40% and -64.82%.

Gross Margin	13.91%
Operating Margin	-153.40%
Pretax Margin	-84.05%
Profit Margin	-64.82%
EBITDA Margin	-126.53%
EBIT Margin	-153.40%
FCF Margin	n/a

Dividends & Yields

Kangstem Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-42.69%
Shareholder Yield	-42.69%
Earnings Yield	-7.39%
FCF Yield	-13.84%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Kangstem Biotech has an Altman Z-Score of 0.06. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.06
Piotroski F-Score	n/a